Moderna and Thermo Fisher Scientific announced long-term strategic collaboration
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
On Feb. 18, 2022, the WHO announced the first six countries that will receive the technology needed to…
On Feb. 18, 2022, the U.S. Centers for Disease Control and Prevention (CDC) released the 2022 recommended immunization…
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
On Feb. 16, 2022, BioNTech announced it had introduced its approach to establishing scalable vaccine production by developing…
On Feb. 15, 2022, Pfizer announced that the European Medicines Agency had approved the companyメs 20-valent pneumococcal conjugate…
On Feb. 14, 2022, Novavax announced that the Singapore Health Sciences Authority (HSA) had issued interim authorization for…
On Feb. 14, 2022, Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional…
On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…
On Feb. 10, 2022, Scripps Research announced that the COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the…
On Feb. 8, 2022, Moderna announced a new supply agreement with the government of Colombia for 10.8 million…
On Feb. 8, 2022, a research team led at Boston University School of Public Health reported on links…
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
On Jan. 31, 2022, Moderna announced the U.S. Food and Drug Administration (FDA) had approved the Biologics License…
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
On Jan. 28, 2022, the WHO announced that COVID-19 information had reached 1,292,209 people through Viamoメs 3-2-1 Platform…
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…
On Jan. 25, 2022, Pfizer and BioNTech announced the initiation of a clinical study to evaluate the safety,…
On Jan. 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
On Jan. 24, 2022, the University of Oxford announced that a third booster dose of either the ChAdOx1…